S
Sanofi
13F filer · CIK 0001121404Reported Jul 28, 2026
Net buyer this quarter
13F portfolio value$534MU.S. long equity reported on 13F
Positions102 new · 1 closed
Net flow last quarter+$22.9MBuys minus sells
Top 10 positions weight100.0%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Jul 28, 202610 positions | |||||
| $165M | 30.86% | 12.95% | Not reported | Q4 2024 | |
| $110M | 20.54% | 7.87% | Not reported | Q4 2024 | |
| $64.8M | 12.14% | 4.17% | Not reported | Q4 2024 | |
| $55.5M | 10.39% | 2.82% | -33.3% | Q4 2024 | |
| $37.3M | 6.98% | 4.16% | New | Q2 2026 | |
| $36.1M | 6.76% | 8.15% | Not reported | Q1 2026 | |
| $32.7M | 6.12% | 2.01% | Not reported | Q4 2025 | |
| $16.5M | 3.10% | 2.32% | New | Q2 2026 | |
| $13.5M | 2.53% | 10.44% | Not reported | Q3 2025 | |
| $3.11M | 0.58% | 1.03% | Not reported | Q4 2024 | |
| Q1 2026Reported May 7, 20269 positions | |||||
| $106M | 31.44% | 14.98% | Not reported | Q4 2024 | |
| $77.8M | 23.17% | 7.93% | Not reported | Q4 2024 | |
| $56M | 16.67% | 4.18% | Not reported | Q4 2024 | |
| $30.4M | 9.04% | 2.83% | Not reported | Q4 2024 | |
| $29.2M | 8.69% | 8.15% | New | Q1 2026 | |
| $18.5M | 5.52% | 2.02% | Not reported | Q4 2025 | |
| $14.3M | 4.25% | 10.44% | Not reported | Q3 2025 | |
| $2.51M | 0.75% | 1.07% | Not reported | Q4 2024 | |
| $1.57M | 0.47% | 1.67% | Not reported | Q4 2024 | |
| Q4 2025Reported Feb 11, 20268 positions | |||||
| $97M | 31.24% | 15.04% | Not reported | Q4 2024 | |
| $91.5M | 29.47% | 7.94% | Not reported | Q4 2024 | |
| $46.2M | 14.90% | 4.23% | Not reported | Q4 2024 | |
| $39.8M | 12.84% | 2.93% | Not reported | Q4 2024 | |
| $17.8M | 5.74% | 10.44% | Not reported | Q3 2025 | |
| $16M | 5.16% | 2.07% | New | Q4 2025 | |
| $1.23M | 0.40% | 1.08% | Not reported | Q4 2024 | |
| $810K | 0.26% | 1.90% | Not reported | Q4 2024 | |
| Q3 2025Reported Nov 4, 20259 positions | |||||
| $100M | 38.56% | 15.16% | Not reported | Q4 2024 | |
| $59.7M | 22.91% | 4.23% | Not reported | Q4 2024 | |
| $39M | 14.98% | 7.99% | Not reported | Q4 2024 | |
| $25.2M | 9.67% | 2.98% | Not reported | Q4 2024 | |
| $19M | 7.28% | 10.44% | New | Q3 2025 | |
| $11.6M | 4.46% | 0.91% | Not reported | Q2 2025 | |
| LTLVTXLAVA Therapeutics NV | $2.99M | 1.15% | 7.30% | Not reported | Q4 2024 |
| $2.11M | 0.81% | 1.36% | Not reported | Q4 2024 | |
| $483K | 0.19% | 1.98% | Not reported | Q4 2024 | |
Premium opens every quarter this fund has filed